Drug Trial Radar · NCT05583344
Phase 2b Study of GSK4532990 in Adults With NASH
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
284
Actual
Start
Jan 2, 2023
Primary completion
Jan 31, 2026
Study completion Oct 15, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.
Conditions
- Nonalcoholic Fatty Liver Disease
- Non-alcoholic Fatty Liver Disease
Interventions
GSK4532990Drug
GSK4532990 will be administered.
PlaceboDrug
Placebo will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving ≥ 1 Stage Improvement in Histological Fibrosis with no Worsening of NASH - F3 CohortTime frame: At Week 52
- Percentage of Participants Achieving NASH Resolution with no Worsening of Fibrosis - F3 CohortTime frame: At Week 52
Locations
171 sites in 17 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Homewood, Alabama
GSK Investigational Site
Chandler, Arizona
GSK Investigational Site
Chandler, Arizona
GSK Investigational Site
Mesa, Arizona
GSK Investigational Site
Jonesboro, Arkansas
GSK Investigational Site
North Little Rock, Arkansas
GSK Investigational Site
Huntington Park, California
GSK Investigational Site
La Jolla, California
GSK Investigational Site
Orange, California
GSK Investigational Site
Poway, California
GSK Investigational Site
Rialto, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
Santa Ana, California
GSK Investigational Site
Van Nuys, California
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Bradenton, Florida
GSK Investigational Site
Coral Gables, Florida
GSK Investigational Site
Fort Myers, Florida
GSK Investigational Site
Hallandale, Florida
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
Homestead, Florida
GSK Investigational Site
Jupiter, Florida
GSK Investigational Site
Lakewood Rch, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami Lakes, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Athens, Georgia
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Marietta, Georgia
GSK Investigational Site
Snellville, Georgia
GSK Investigational Site
Indianapolis, Indiana
GSK Investigational Site
South Bend, Indiana
GSK Investigational Site
Iowa City, Iowa
GSK Investigational Site
Topeka, Kansas
GSK Investigational Site
Bastrop, Louisiana
GSK Investigational Site
Marrero, Louisiana
GSK Investigational Site
Metairie, Louisiana
Showing 40 of 171 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.